The Top 100 Pharmaceutical Companies

The Top 100 Pharmaceutical Companies, determined by total sales in 2011 - see below for 2010 and  2009: They are listed in descending order with the sales in 2011 in $ million; Pfizer ...

Pain

Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in term...

Bioscience - news, views, reports and blogs

Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural scienc...

Biosimilars - news, reports, views and blogs

Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusi...

CaptureSelect

BAC’s CaptureSelect products are affinity ligands and affinity resins created by a proprietary technology based on Camelid-derived single domain antibody fragments for the purification of biop...

OncoEthix in-licenses Mitsubishi Tanabe's cancer compound

Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508) granted OncoEthix S.A. (Lausanne, Switzerland) exclusive, worldwide rights to cancer compound OTX015. Mitsubishi retains rights to the compound...

Dezima Pharma in-licenses CETP inhibitor program from Mitsubishi Tanabe Pharma

Dezima Pharma announced the in-licensing of a cholesteryl ester transfer protein inhibitor DEZ-001 from Mitsubishi Tanabe Pharma. Terms of the deal were not disclosed. Related items: Report: Partneri...

[Oncoethix] gets rights to [Mitsubishi Tanabe]'s bromodomain inhibitor for cancer

[Mitsubishi Tanabe Pharma Corp.] has granted [Oncoethix SA] (oncology) exclusive worldwide rights, excluding certain Asian territories, to its Phase I small-molecule bromodomain inhibitor indicated fo...

Mitsubishi Tanabe: Company Profile

Mitsubishi Tanabe, a top pharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years. Return to top 50 pharma list Summary Website: Mits...

OncoEthix, Mitsubishi Tanabe Pharma deal

Mitsubishi Tanabe

Mitsubishi Tanabe is a top pharmaceutical company based in Tokyo, Japan. The company was formed in October, 2007 with the merger of Tanabe Seiyaku Co., Ltd. and Mitsubishi Pharma (formed in 2001 with...

Mitsubishi Tanabe Pharma in-licenses CETP inhibitor to Dezima Pharma

Dezima Pharma ('Dezima'), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the in-licensing of a cholesteryl ester transfer protein (CETP) inhibitor...

OncoEthix In-Licenses OTX015, an anticancer Bromodomain inhibitor from Mitsubishi Tanabe Pharma Corporation

Lausanne, Switzerland, June 15 - OncoEthix, a Swiss-based company specializing in oncology drug development, has in-licensed a compound, OTX015, from Mitsubishi Tanabe Pharma Corporation (MTPC).&...

Neuroprotective effects of a novel water-soluble poly(ADP-ribose) polymerase-1 inhibitor, MP-124, in in vitro and in vivo models of cerebral ischemia.

Cerebral ischemia induces excessive activation of poly(ADP-ribose) polymerase-1 (PARP-1), leading to neuronal cell death and the development of post-ischemic dysfunction. Blockade of PARP-related sign...

Fused bicyclic heteroarylpiperazine-substituted l-prolylthiazolidines as highly potent DPP-4 inhibitors lacking the electrophilic nitrile group.

Hypoglycemic agents with a mechanism of depeptidyl peptidase IV (DPP-4) inhibition are suitable for once daily oral dosing. It is difficult to strike a balance between inhibitory activity and duration...

Deal watch: Phase III antibody targeting tumour pH acquired in Prometheus deal.

Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs.

Deal watch: Epizyme-Celgene deal signals interest in new class of epigenetic drugs.